Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
How This Top Small-Cap Growth Fund Wins Big
In a stock market that favors the giants, it's still possible to reap big gains investing in Wall Street's small fries. The post How This Top Small-Cap Growth Fund Wins Big appeared first on Investor's Business Daily.
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Anthony Petrone - Mizuho Group Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference Call on Monday, March 3rd, 2025. At this time, all participants are in a listen-only mode.
Wall Street Analysts Look Bullish on Adma Biologics (ADMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session.
Pharma Stock Poised to Bounce Off Support
Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
Adma Biologics (ADMA) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $16.92, denoting a +0.3% change from the preceding trading day.
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients. ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.98% move from its prior day's close.
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
Adma Biologics (ADMA) closed the most recent trading day at $16.17, moving -0.12% from the previous trading session.
